Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.

Haematologica·2026
Same author

Resolution of R-loops and transcription-replication conflicts by SETX-BRCA1-BARD1 complex.

Nature structural & molecular biology·2026
Same author

Universal progression of structure and dynamics in colloidal nanocrystal gels during salt-accelerated aging.

Science advances·2026
Same author

Towards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure.

Stem cells translational medicine·2026
Same author

Ancestry-associated social and genomic hallmarks linked with inferior outcome in elderly acute myeloid leukemia.

BMC cancer·2025
Same author

Codanin-1, defective in congenital dyserythropoietic anemia I (CDA-I), regulates erythroid differentiation.

Annals of hematology·2025

Related Experiment Video

Updated: Jun 24, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Fanconi anemia.

Allison M Green1, Gary M Kupfer

  • 1Section of Pediatric Hematology-Oncology, Department of Pathology, Yale University School of Medicine, 333 Cedar Street LMP 2073, PO Box 208064, New Haven, CT 06520-8064, USA.

Hematology/Oncology Clinics of North America
|March 31, 2009
PubMed
Summary
This summary is machine-generated.

Fanconi anemia (FA) is a rare genetic disorder affecting bone marrow and increasing cancer risk. Understanding FA pathway functions is crucial for improving treatments and survival rates for affected children.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

Area of Science:

  • Genetics
  • Hematology
  • Oncology

Background:

  • Fanconi anemia (FA) is a rare, inherited bone marrow failure syndrome.
  • FA is associated with a high risk of developing acute myelogenous leukemia and solid tumors.
  • Improved treatments have increased survival rates for FA patients into adulthood.

Purpose of the Study:

  • To review the current clinical presentation, diagnosis, and treatment of Fanconi anemia.
  • To explore the molecular aspects and cellular functions of the Fanconi anemia pathway.
  • To highlight the need for further research into FA pathway functions to improve patient outcomes.

Main Methods:

  • Literature review of clinical and molecular aspects of Fanconi anemia.
  • Synthesis of current knowledge on FA diagnosis and treatment strategies.
  • Analysis of the known components and proposed functions of the FA DNA repair pathway.

Main Results:

  • FA presents with a range of clinical manifestations including bone marrow failure and increased cancer susceptibility.
  • Current treatments have improved patient survival but do not address the underlying molecular defects.
  • The precise cellular functions of the FA pathway proteins remain largely unknown.

Conclusions:

  • Further elucidation of FA pathway functions is essential for developing more effective therapies.
  • Improved understanding may lead to targeted treatments reducing long-term complications and mortality.
  • This review provides a foundation for future research into Fanconi anemia pathogenesis and treatment.